An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Slides:

Advertisements

Similar presentations

Atrial Fibrillation and Heart Failure Andrew A. Grace, MB, PhD, FRCP Heart Failure Clinics Volume 9, Issue 4, (October 2013) DOI: /j.hfc

Advertisements

Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention.

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial.

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST) Kirsten E. Fleischmann,

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserve–guided.

Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi- intervention in type 2 diabetes: The randomized controlled Asker.

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation Hany S. Abed, BPharm, MBBS, PhD,

Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study

Rationale and design of the ATTRACT Study: A multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention.

A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and.

Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

American Heart Journal

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice Manesh R.

Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular.

Hemoglobin levels and new-onset heart failure in the community

A peculiar medical cardioversion of atrial fibrillation with glucose infusion—a rare cause of atrial fibrillation: hypoglycemia Savas Celebi, MD The.

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance Judith.

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: Rationale and design of the Brazilian Intervention.

Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry Sean D. Pokorney, MD, MBA,

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

An Unusual Cause of Leg Ulcerations

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Volume 137, Issue 2, Pages (February 2010)

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Development of Clinical Practice Guidelines in the Care of People With Kidney Disease: Core Curriculum 2016 Angela C. Webster, PhD, Evi V. Nagler, MD,

Jeffrey H. Barsuk, MD, MS, Elaine R

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

Impact of 64-Slice Multidetector Computed Tomography on Other Diagnostic Studies for Coronary Artery Disease Alex J. Auseon, DO, Sunil S. Advani, MD,

Gastric Diverticulum: A Rare Cause of Refractory Epigastric Pain

The Value of Percutaneous Coronary Intervention in Aortic Valve Stenosis with Coronary Artery Disease Ronny Alcalai, MD, Nicola Viola, MD, Morris Mosseri,

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey Gregory Y.H. Lip, MD, Cécile Laroche, MSc, Gheorghe-Andrei Dan,

Trend in Mortality after Stroke with Atrial Fibrillation

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Differences in the Clinical Features and Outcomes in African Americans and Whites with Myocardial Infarction Rajendra H. Mehta, MD, MS, David Marks,

The Reply The American Journal of Medicine

Why surgery won the SYNTAX trial and why it matters

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Repeated Hemoglobin A1C Ordering in the VA Health System

Molly E. Waring, PhD, Jane S

Coronary Artery Disease in Women: Shyly Bold?

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Yariv Gerber, PhD, L. Joseph Melton, MD, Sheila M

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

Value Over Volume Annals of Emergency Medicine

The American Journal of Medicine

Jeffrey H. Barsuk, MD, MS, Elaine R

Screening and Treatment of Vitamin D Deficiency on Hospital Admission: Is There a Benefit for Medical Inpatients? Lena Grädel, MD, Meret Merker, BMSc,

Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Dialysis Research and N-of-1 Trials: Made for Each Other?

Commentary: Judgment day: Should you add atrial fibrillation ablation?

Falls in Older Adults: Risk Assessment, Management and Prevention

Forest plot illustrating the risk ratio of major bleeding

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Presentation transcript:

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI) C. Michael Gibson, MS, MD, Roxana Mehran, MD, Christoph Bode, MD, Johnathan Halperin, MD, Freek Verheugt, MD, Peter Wildgoose, PhD, Martin van Eickels, MD, Gregory Y.H. Lip, MD, Marc Cohen, MD, Steen Husted, MD, Eric Peterson, MD, Keith Fox, MD American Heart Journal Volume 169, Issue 4, Pages 472-478.e5 (April 2015) DOI: 10.1016/j.ahj.2014.12.006 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure Study design of PIONEER AF-PCI. American Heart Journal 2015 169, 472-478.e5DOI: (10.1016/j.ahj.2014.12.006) Copyright © 2014 Elsevier Inc. Terms and Conditions